Evaluation of Proclarix in the diagnostic work-up of prostate cancer.

Journal: BJUI compass
Published Date: Sep 29, 2023

Abstract

OBJECTIVES: The use of multiparametric magnetic resonance imaging (mpMRI) has been widely adopted in the diagnostic work-up for suspicious prostate cancer (PCa) and is recommended in most current guidelines. However, mpMRI lesions are often indeterminate and/or turn out to be false-positive on prostate biopsy. The aim of this work was to evaluate Proclarix, a biomarker test for the detection of relevant PCa, regarding its diagnostic value in all men before biopsy and in men with indeterminate lesions on mpMRI (PI-RADS 3) during work-up for PCa.

Authors

  • Basil Kaufmann
    Department of Urology University Hospital Zurich Zurich Switzerland.
  • Sharon Fischer
    Department of Urology University Hospital Zurich Zurich Switzerland.
  • Alcibiade Athanasiou
    Proteomedix AG Zurich Switzerland.
  • Noémie Lautenbach
    Department of Urology University Hospital Zurich Zurich Switzerland.
  • Anja Wittig
    Proteomedix AG Zurich Switzerland.
  • Uwe Bieri
    Department of Urology University Hospital Zurich Zurich Switzerland.
  • Florian A Schmid
    Department of Urology University Hospital Zurich Zurich Switzerland.
  • Franz von Stauffenberg
    Department of Urology University Hospital Zurich Zurich Switzerland.
  • Thomas Scherer
    Department of Urology University Hospital Zurich Zurich Switzerland.
  • Daniel Eberli
    Department of Urology University Hospital Zurich Zurich Switzerland.
  • Michael A Gorin
    Milton and Carroll Petrie Department of Urology Icahn School of Medicine at Mount Sinai New York New York USA.
  • Ralph Schiess
    Proteomedix AG Zurich Switzerland.
  • Cédric Poyet
    Department of Urology University Hospital Zurich Zurich Switzerland.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals